Total Payments
$176,185
2023 Payments
$46,361
Companies
16
Transactions
153
Medicare Patients
280
Medicare Billing
$196,446
Payment Breakdown by Category
Consulting$98,413 (55.9%)
Other$59,033 (33.5%)
Travel$15,733 (8.9%)
Food & Beverage$3,007 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $98,413 | 26 | 55.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,325 | 16 | 28.6% |
| Travel and Lodging | $15,733 | 48 | 8.9% |
| Honoraria | $5,850 | 4 | 3.3% |
| Food and Beverage | $3,007 | 58 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,858 | 1 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $53,559 | 55 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $38,859 | 32 | $0 (2019) |
| Astellas Pharma Global Development | $25,000 | 1 | $0 (2023) |
| SERVIER PHARMACEUTICALS LLC | $12,864 | 10 | $0 (2023) |
| Agios Pharmaceuticals, Inc. | $12,354 | 16 | $0 (2021) |
| Janssen Global Services, LLC | $5,882 | 11 | $0 (2019) |
| Celgene Corporation | $4,297 | 5 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $4,250 | 8 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $4,140 | 2 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,960 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $46,361 | 22 | Astellas Pharma Global Development ($25,000) |
| 2022 | $17,190 | 16 | ABBVIE INC. ($12,184) |
| 2021 | $13,164 | 10 | GlaxoSmithKline, LLC. ($3,900) |
| 2020 | $21,029 | 11 | AbbVie Inc. ($11,659) |
| 2019 | $31,154 | 34 | AbbVie, Inc. ($17,806) |
| 2018 | $21,871 | 34 | Novartis Pharmaceuticals Corporation ($10,294) |
| 2017 | $25,417 | 26 | Novartis Pharmaceuticals Corporation ($21,442) |
All Payment Transactions
153 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $125.25 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2023 | Astellas Pharma Global Development | Xospata (Drug) | Consulting Fee | Cash or cash equivalent | $25,000.00 | General |
| Category: Oncology | ||||||
| 06/01/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $486.50 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 06/01/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $28.47 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $2,740.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $472.81 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $319.46 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $108.61 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $44.12 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/14/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $7,310.00 | General |
| Category: Oncology | ||||||
| 04/14/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $358.00 | General |
| Category: Oncology | ||||||
| 03/20/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: ONCOLOGY | ||||||
| 03/03/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $54.99 | General |
| Category: Oncology | ||||||
| 03/03/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $39.99 | General |
| Category: Oncology | ||||||
| 03/03/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $30.01 | General |
| Category: Oncology | ||||||
| 03/03/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: Oncology | ||||||
| 03/02/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $1,021.80 | General |
| Category: Oncology | ||||||
| 03/02/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | Cash or cash equivalent | $303.97 | General |
| Category: Oncology | ||||||
| 01/13/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,070.00 | General |
| 01/13/2023 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $2,070.00 | General |
| 10/07/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,687.50 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 62 | 554 | $177,102 | $47,650 |
| 2022 | 2 | 70 | 611 | $160,451 | $51,004 |
| 2021 | 3 | 82 | 596 | $158,543 | $52,449 |
| 2020 | 2 | 66 | 598 | $156,508 | $45,344 |
Total Patients
280
Total Services
2,359
Medicare Billing
$196,446
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 35 | 356 | $91,136 | $27,899 | 30.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 198 | $85,966 | $19,751 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 342 | $87,552 | $27,816 | 31.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 269 | $72,899 | $23,188 | 31.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 35 | 329 | $84,224 | $27,933 | 33.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 32 | 249 | $67,479 | $22,213 | 32.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 18 | $6,840 | $2,303 | 33.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 33 | 370 | $94,720 | $24,478 | 25.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 33 | 228 | $61,788 | $20,866 | 33.8% |
About Dr. Guido Marcucci, M.D
Dr. Guido Marcucci, M.D is a Hematology healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1689689127.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Guido Marcucci, M.D has received a total of $176,185 in payments from pharmaceutical and medical device companies, with $46,361 received in 2023. These payments were reported across 153 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($98,413).
As a Medicare-enrolled provider, Marcucci has provided services to 280 Medicare beneficiaries, totaling 2,359 services with total Medicare billing of $196,446. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Medical Oncology
- Location Duarte, CA
- Active Since 07/31/2006
- Last Updated 11/13/2020
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1689689127
Products in Payments
- RYDAPT (Drug) $37,981
- VENCLEXTA (Drug) $30,090
- Xospata (Drug) $25,000
- Venclexta (Drug) $23,469
- TIBSOVO (Drug) $16,053
- Tibsovo (Drug) $9,134
- Rezlidhia (Drug) $4,250
- Blincyto (Biological) $2,921
- ONUREG (Drug) $2,076
- MYLOTARG (Drug) $396.12
- PROMACTA (Drug) $116.56
- Yescarta (Drug) $76.76
- VYXEOS (Drug) $70.73
- INREBIC (Drug) $48.53
- Nplate (Biological) $10.66
- Kyprolis (Drug) $5.40
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Duarte
Mr. Vinod Pullarkat, M.d, M.D
Hematology — Payments: $639,378
Hematology $639,378
Alex Herrera, Md, MD
Hematology — Payments: $165,071
Hematology $165,071
Dr. Joseph Chao, M.d, M.D
Hematology — Payments: $152,551
Hematology $152,551
John Baird, Md, MD
Hematology — Payments: $48,735
Hematology $48,735
Dr. Idoroenyi Amanam, M.d, M.D
Hematology — Payments: $22,530
Hematology $22,530
Dr. Swetha Thiruvengadam, M.d, M.D
Hematology — Payments: $21,889
Hematology $21,889